<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00115037</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAAOSL014851, 708534</org_study_id>
    <nct_id>NCT00115037</nct_id>
  </id_info>
  <brief_title>Managing Alcoholism in People Who Do Not Respond to Naltrexone</brief_title>
  <acronym>EXTEND</acronym>
  <official_title>Non-Response to Naltrexone (NTX): Next Steps in Managing Alcoholism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study involving treatment for alcohol dependence (alcoholism). The study will
      combine motivational enhancement therapy and cognitive behavioral therapy (combined
      behavioral intervention, or CBI) and tests the benefits of continued/discontinued treatment
      with naltrexone in a randomized placebo-controlled trial. CBI may have advantages in
      motivating patients to greater medication adherence and may address psychosocial factors that
      may limit the effects of naltrexone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Naltrexone has been established as an efficacious medication to treat alcohol dependence but
      studies thus far have focused mostly on the acute phase of treatment rather than long-term
      management and have not offered alternative treatment strategies when patients do not respond
      to an initial course of naltrexone. For these initial non-responders to naltrexone, it is
      unclear what adjustments to treatment should be made to increase the likelihood of treatment
      success. We are unaware of previous research focused specifically on naltrexone non-response.
      Pilot data from ongoing trials at our center, however, suggest that up to a third of patients
      fail to respond to naltrexone. Moreover, these non-responsive patients go on to have the
      worst outcomes during the next 6 months of treatment if maintained on the same combination of
      naltrexone and medication management (MM). We propose to augment medication management with a
      combination of motivational enhancement therapy and cognitive behavioral therapy (combined
      behavioral intervention - CBI) and to test the benefits of continued/discontinued treatment
      with naltrexone in a randomized placebo-controlled trial. Clinical strategies for second line
      treatments often favor switching treatments rather than augmentation. However, there may be
      synergies between naltrexone and CBI that were not apparent with medication management.
      Specifically, CBI may have advantages in motivating patients to greater medication adherence
      (a leading cause of naltrexone treatment failure) and CBI may address psychosocial factors
      that limited or attenuated the effects of naltrexone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Count of Responders and Non-responders in Phase 1</measure>
    <time_frame>8 weeks</time_frame>
    <description>This is the number of patients who responded to phase 1 treatment based on the definition that subjects were randomly assigned to.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Heavy Drinking Days</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percentage of days with heavy drinking, where heavy drinking is 4 (5) or more drinks for females (males) in a 24 hour period.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">302</enrollment>
  <condition>Alcoholism</condition>
  <arm_group>
    <arm_group_label>Phase 1 Liberal Response</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>From the start of baseline subjects were randomly assigned to this arm which defined relapse/non-responder as having 5 or heavy drinking days in the first 8 weeks of treatment otherwise the subject was considered a responder.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Stringent Response</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>From the start of baseline subjects were randomly assigned to this arm which defined relapse/non-responder as having 2 or heavy drinking days in the first 8 weeks of treatment otherwise the subject was considered a responder.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 nalt and tele for responders</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2: Naltrexone and telephone counseling for responders.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 nalt, MM and CBI for NR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2: naltrexone, Medication Management (MM) and Combined Behavioral Intervention (CBI) for non-responders (NR).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 placebo, MM and CBI for NR</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phase 2: placebo, Medication Management (MM) and Combined Behavioral Intervention (CBI) for non-responders (NR)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 naltrexone for responders</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2: Naltrexone and TAU for phase 1 responders.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.</description>
    <arm_group_label>Phase 1 Liberal Response</arm_group_label>
    <arm_group_label>Phase 1 Stringent Response</arm_group_label>
    <arm_group_label>Phase 2 nalt and tele for responders</arm_group_label>
    <arm_group_label>Phase 2 nalt, MM and CBI for NR</arm_group_label>
    <arm_group_label>Phase 2 naltrexone for responders</arm_group_label>
    <other_name>ReVia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo comparer for 16 weeks in phase 2.</description>
    <arm_group_label>Phase 2 placebo, MM and CBI for NR</arm_group_label>
    <other_name>placebo pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Medication Management (MM)</intervention_name>
    <description>Brief manual-based therapy for up to 8 weeks during phase 1, 16 during phase 2.</description>
    <arm_group_label>Phase 2 nalt, MM and CBI for NR</arm_group_label>
    <arm_group_label>Phase 2 placebo, MM and CBI for NR</arm_group_label>
    <other_name>MM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Combined Behavioral Intervention (CBI)</intervention_name>
    <description>45-60 minute sessions with a certified therapist focused on resolving ambivalence and skill building. Number of sessions guided by achievement of goals identified within treatment plan; minimum 9, maximum 20 sessions over 16 weeks.</description>
    <arm_group_label>Phase 2 nalt, MM and CBI for NR</arm_group_label>
    <arm_group_label>Phase 2 placebo, MM and CBI for NR</arm_group_label>
    <other_name>CBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Telephone Counseling</intervention_name>
    <description>Bi-weekly telephone calls lasting 15-20 minutes focused on the same content as MM.</description>
    <arm_group_label>Phase 2 nalt and tele for responders</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Current DSM-IV diagnosis of alcohol dependence using the MINI.

          -  Meets the following drinking criteria as measured by the Timeline Followback (TLFB): *
             drank within 30 days of randomization; * reports a minimum of 48 standard alcoholic
             drinks (avg. 12 drinks/wk.) in a consecutive 30-day period over the 90-day period
             prior to intake; and * has 2 or more days of heavy drinking (defined as over 5 drinks
             per day in males and over 4 drinks per day in females) in this same pre-treatment
             period, prior to intake.

          -  Prior to starting NTX, scores below 8 on the Clinical Inventory of Withdrawal from
             Alcohol (CIWA), and at least 3 consecutive days of abstinence (2 days abstinence will
             be permitted with approval by the principal investigator) directly prior to
             randomization, as determined by Subject report and breathalyzer measures

          -  Speaks, understands and prints in English.

        Exclusion Criteria:

          -  Has abused or been dependent on opiates in the past 12 months, or evidence of opiate
             use in month prior to treatment, as assessed by subject report and intake urine drug
             screen. Use of prescription opioids prior to treatment entry is allowed at the
             discretion of the investigator. However, subjects must be free from use at the time of
             randomization.

          -  Meets DSM IV criteria for current dependence, abuse, or dependence in partial
             remission on any substance other than alcohol (except nicotine and marijuana).
             Subjects who test positive on the urine drug screen (with the exception of THC) at the
             initial visit (a repeat UDSis permitted in cases that are not clear. The repeat UDS
             should be at least 5 days after the initial test)

          -  Has a lifetime DSM-IV diagnosis of schizophrenia or any psychotic disorder. Has a
             current DSM-IV diagnosis of post-traumatic stress disorder (PTST) or bipolar disorder,
             or any disorder that may interfere with study participation, at the discretion of the
             investigator.

          -  Hepatocellular disease indicated by elevations of SGPT (ALT) and SGOT (AST) of at
             least 5 times normal, or elevated bilirubin (of 1.3 or higher), as evidenced by the
             most recent lab results prior to randomization. (documentation of Gilberts syndrome
             will not constitute an exclusion despite elevated bilirubin).

          -  Has evidence of significant hematological, pulmonary, endocrine, cardiovascular, renal
             or gastrointestinal disease that the principal investigator considers a risk to
             participation.

          -  Has taken any psychotropic medications (or disulfiram) regularly within the last seven
             days prior to randomization or needs immediate treatment with a psychotropic
             medication (with the exception of detoxification medications or benadryl used
             sparingly for sleep). The required washout period for fluoxetine (ProzacÂ®) is 14 days
             prior to randomization, and the required washout period for other psychotropic
             medications is 7 days prior to randomization.

          -  Has taken any detoxification medication on the day of randomization.

          -  Tests positive on a pregnancy test, is contemplating pregnancy in the next 12 months,
             is nursing, or is not using an effective contraceptive method if the subject is of
             child-bearing potential.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David W. Oslin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania Treatment Research Center, Chestnut Street</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 20, 2005</study_first_submitted>
  <study_first_submitted_qc>June 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2005</study_first_posted>
  <results_first_submitted>September 14, 2017</results_first_submitted>
  <results_first_submitted_qc>August 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2019</results_first_posted>
  <last_update_submitted>August 28, 2019</last_update_submitted>
  <last_update_submitted_qc>August 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>David Oslin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Alcoholism</keyword>
  <keyword>alcohol abuse</keyword>
  <keyword>therapy</keyword>
  <keyword>drug resistance</keyword>
  <keyword>naltrexone</keyword>
  <keyword>patient care management</keyword>
  <keyword>human subject</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were recruited through advertisements in the local media, referrals from physicians, or self referrals.</recruitment_details>
      <pre_assignment_details>All participants were offered medically monitored outpatient detox as needed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase1: Liberal</title>
          <description>Relapse/non-responder defined as having 5 or more heavy drinking days in the first 8 weeks of treatment otherwise the subject was considered a responder.
Naltrexone: 100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.</description>
        </group>
        <group group_id="P2">
          <title>Phase1: Stringent</title>
          <description>Relapse/non-responder defined as having 2 or more heavy drinking days in the first 8 weeks of treatment otherwise the subject was considered a responder.
Naltrexone: 100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.</description>
        </group>
        <group group_id="P3">
          <title>Phase2: Responder - Naltx (Usual Care)</title>
          <description>Phase 2: Naltrexone and TAU for phase 1 responders. Naltrexone: 100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.</description>
        </group>
        <group group_id="P4">
          <title>Phase2: Responder - Naltx+Phone (TDM)</title>
          <description>Phase 2: Naltrexone and telephone counseling for responders. Naltrexone: 100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2. Telephone Counseling: Bi-weekly telephone calls lasting 15-20 minutes focused on the same content as MM.</description>
        </group>
        <group group_id="P5">
          <title>Phase2: Non-responder - Naltx, MM and CBI</title>
          <description>Phase 2: naltrexone, Medication Management (MM) and Combined Behavioral Intervention (CBI) for non-responders (NR).
Naltrexone: 100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2. Medication Management (MM): Brief manual-based therapy for up to 8 weeks during phase 1, 16 during phase 2.
Combined Behavioral Intervention (CBI): 45-60 minute sessions with a certified therapist focused on resolving ambivalence and skill building. Number of sessions guided by achievement of goals identified within treatment plan; minimum 9, maximum 20 sessions over 16 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Phase2: Non-responder - Placebo, MM and CBI</title>
          <description>Phase 2: placebo, Medication Management (MM) and Combined Behavioral Intervention (CBI) for non-responders (NR) placebo: placebo comparer for 16 weeks in phase 2. Medication Management (MM): Brief manual-based therapy for up to 8 weeks during phase 1, 16 during phase 2.
Combined Behavioral Intervention (CBI): 45-60 minute sessions with a certified therapist focused on resolving ambivalence and skill building. Number of sessions guided by achievement of goals identified within treatment plan; minimum 9, maximum 20 sessions over 16 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="150"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="123"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="91"/>
                <participants group_id="P4" count="92"/>
                <participants group_id="P5" count="34"/>
                <participants group_id="P6" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="76"/>
                <participants group_id="P4" count="77"/>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase1: Liberal</title>
          <description>Definition B of heavy drinker: 5+ days of binge drinking</description>
        </group>
        <group group_id="B2">
          <title>Phase1: Stringent</title>
          <description>Definition A of heavy drinker: 2+ days of binge drinking</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="152"/>
            <count group_id="B2" value="150"/>
            <count group_id="B3" value="302"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.70" spread="10.40"/>
                    <measurement group_id="B2" value="48.49" spread="10.36"/>
                    <measurement group_id="B3" value="48.6" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="292"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="214"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Count of Responders and Non-responders in Phase 1</title>
        <description>This is the number of patients who responded to phase 1 treatment based on the definition that subjects were randomly assigned to.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Liberal Response</title>
            <description>From the start of baseline subjects were randomly assigned to this arm which defined relapse/non-responder as having 5 or more heavy drinking days in the first 8 weeks of treatment otherwise the subject was considered a responder.
Naltrexone: 100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Stringent Response</title>
            <description>From the start of baseline subjects were randomly assigned to this arm which defined relapse/non-responder as having 2 or more heavy drinking days in the first 8 weeks of treatment otherwise the subject was considered a responder.
Naltrexone: 100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Responders and Non-responders in Phase 1</title>
          <description>This is the number of patients who responded to phase 1 treatment based on the definition that subjects were randomly assigned to.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Heavy Drinking Days</title>
        <description>Percentage of days with heavy drinking, where heavy drinking is 4 (5) or more drinks for females (males) in a 24 hour period.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Naltrexone for Responders</title>
            <description>Phase 2: Naltrexone and TAU for phase 1 responders.
Naltrexone: 100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 Nalt and Tele for Responders</title>
            <description>Phase 2: Naltrexone and telephone counseling for responders.
Naltrexone: 100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.
Telephone Counseling: Bi-weekly telephone calls lasting 15-20 minutes focused on the same content as MM.</description>
          </group>
          <group group_id="O3">
            <title>Phase 2 Nalt, MM and CBI for NR</title>
            <description>Phase 2: naltrexone, Medication Management (MM) and Combined Behavioral Intervention (CBI) for non-responders (NR).
Naltrexone: 100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.
Medication Management (MM): Brief manual-based therapy for up to 8 weeks during phase 1, 16 during phase 2.
Combined Behavioral Intervention (CBI): 45-60 minute sessions with a certified therapist focused on resolving ambivalence and skill building. Number of sessions guided by achievement of goals identified within treatment plan; minimum 9, maximum 20 sessions over 16 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Phase 2 Placebo, MM and CBI for NR</title>
            <description>Phase 2: placebo, Medication Management (MM) and Combined Behavioral Intervention (CBI) for non-responders (NR)
placebo: placebo comparer for 16 weeks in phase 2.
Medication Management (MM): Brief manual-based therapy for up to 8 weeks during phase 1, 16 during phase 2.
Combined Behavioral Intervention (CBI): 45-60 minute sessions with a certified therapist focused on resolving ambivalence and skill building. Number of sessions guided by achievement of goals identified within treatment plan; minimum 9, maximum 20 sessions over 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Heavy Drinking Days</title>
          <description>Percentage of days with heavy drinking, where heavy drinking is 4 (5) or more drinks for females (males) in a 24 hour period.</description>
          <units>percentage days of heavy drinking</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="4.8"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="3.2"/>
                    <measurement group_id="O3" value="27.7" lower_limit="2.8" upper_limit="61.6"/>
                    <measurement group_id="O4" value="17.8" lower_limit="0" upper_limit="58.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Phase1: Liberal</title>
          <description>Relapse/non-responder defined as having 5 or more heavy drinking days in the first 8 weeks of treatment otherwise the subject was considered a responder.
Naltrexone: 100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.</description>
        </group>
        <group group_id="E2">
          <title>Phase1: Stringent</title>
          <description>Relapse/non-responder defined as having 2 or more heavy drinking days in the first 8 weeks of treatment otherwise the subject was considered a responder.
Naltrexone: 100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.</description>
        </group>
        <group group_id="E3">
          <title>Phase2: Responder - Naltx (Usual Care)</title>
          <description>Phase 2: Naltrexone and TAU for phase 1 responders. Naltrexone: 100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.</description>
        </group>
        <group group_id="E4">
          <title>Phase2: Responder - Naltx+Phone (TDM)</title>
          <description>Phase 2: Naltrexone and telephone counseling for responders. Naltrexone: 100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2. Telephone Counseling: Bi-weekly telephone calls lasting 15-20 minutes focused on the same content as MM.</description>
        </group>
        <group group_id="E5">
          <title>Phase2: Non-responder - Naltx, MM and CBI</title>
          <description>Phase 2: naltrexone, Medication Management (MM) and Combined Behavioral Intervention (CBI) for non-responders (NR).
Naltrexone: 100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2. Medication Management (MM): Brief manual-based therapy for up to 8 weeks during phase 1, 16 during phase 2.
Combined Behavioral Intervention (CBI): 45-60 minute sessions with a certified therapist focused on resolving ambivalence and skill building. Number of sessions guided by achievement of goals identified within treatment plan; minimum 9, maximum 20 sessions over 16 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Phase2: Non-responder - Placebo, MM and CBI</title>
          <description>Phase 2: placebo, Medication Management (MM) and Combined Behavioral Intervention (CBI) for non-responders (NR) placebo: placebo comparer for 16 weeks in phase 2. Medication Management (MM): Brief manual-based therapy for up to 8 weeks during phase 1, 16 during phase 2.
Combined Behavioral Intervention (CBI): 45-60 minute sessions with a certified therapist focused on resolving ambivalence and skill building. Number of sessions guided by achievement of goals identified within treatment plan; minimum 9, maximum 20 sessions over 16 wee</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Overall the sample size was limited for detecting results in the second phase.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David Oslin, MD</name_or_title>
      <organization>UPENN</organization>
      <phone>215-823-5894</phone>
      <email>oslin@upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

